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Drug Induced Liver Injury (DILI) remains the major
adverse drug event that leads to termination of clinical
development programs and regulatory actions including
failure to approve for marketing, restricted indications,
and withdrawal from the marketplace. The type of DILI
that is most problematic is “idiosyncratic” meaning that
only a very small fraction of treated patients are suscepti-
ble to the DILI. Current preclinical models, even “huma-
nized” ones, do not reliably identify molecules that have
this liability and, conversely predict liabilities in molecule
that are in fact quite safe for the liver. For example, cur-
rent preclinical testing does not detect the DILI potential
of xymelagatran, a drug withdrawn from worldwide mar-
kets due to idiosyncratic hepatotoxicity but would predict
a high liver risk for acetaminophen (paracetamol) even
when taken as directed. Reliable preclinical testing will
probably not be developed until there is greater under-
standing of the mechanisms underlying DILI. Reasoning
that the best models to study DILI are the people who
have actually experienced it, we are capitalizing on the
resources of the US Drug-Induced Liver Injury Network
(DILIN-supported by the National Institutes of Health)
that is collecting genomic DNA and other biospecimens
from patients who have experienced DILI. In addition to
genetic studies, we are partnering with Cellular Dynamics
International to reprogram induced pleuripotent stem
cells from DILIN subjects in whom we have complete exo-
mic DNA sequence with the goal of producing patient-
specific liver cultures, and ultimately, humanized mice.
We are also partnering with the Shanghai Centers for
Disease Control to prospectively collect a variety of bio-
specimens, including whole blood for transcriptome analy-
sis, from patients treated for active tuberculosis as part of
a larger biomarker discovery initiative. We are using
panels of inbred mice to mimic patient population genetic
diversity and to identify genes and pathways that may
underlie DILI susceptibility in patients. Finally, we have
established the DILIsim Initiative which is a public-private
partnership that is building a computer model to synthe-
size the rapidly accumulating data with the goal of predict-
ing DILI liability in drug candidates. DILIsim involves
10 pharmaceutical companies and the Food and Drug
Administration.
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